Protein Degradation Assay Platform

Targeted Protein Degradation Services

Protein Degradation Assay Platform


A protein degradation assay measures whether a compound actually eliminates its target protein from the cell — not simply whether it binds. Our integrated platform pairs mechanism validation with quantitative degradation readouts and rigorous protein quantification methods to give PROTAC and molecular glue programs reproducible, decision-ready data at every stage.

Ternary-complex and E3-ligase mechanism validation
Live-cell HiBiT reporters for DC50, Dmax, and kinetics
Orthogonal confirmation via Western blot, ELISA, HTRF, AlphaLISA

A New Therapeutic Paradigm Needs a New Kind of Assay

Targeted protein degradation has moved from a research curiosity to a validated drug discovery modality, offering a route to disease-causing proteins that resist conventional inhibition. PROTACs and molecular glues do not block an active site; they co-opt the cell's own machinery to remove the target protein entirely. Evaluating a degrader therefore takes more than a single binding or inhibition number — it requires mechanistic evidence that a productive ternary complex has formed, and quantitative proof, generated through reliable protein quantification methods, that the protein of interest is actually being cleared from the cell.

Our Protein Degradation Assay Platform is built around both requirements. It combines mechanism-validation assays, target-engagement and protein detection methods, and quantitative, live-cell degradation measurement, giving discovery teams a single, integrated workflow from early screening through candidate optimization.

What a Protein Degradation Assay Is Actually Measuring

Most degrader compounds ultimately act through the ubiquitin-proteasome system, so understanding this pathway is central to interpreting any protein degradation assay. A protein degradation assay differs fundamentally from a conventional activity or inhibition assay: instead of measuring whether a compound blocks a catalytic function, it measures whether the target protein itself disappears from the cell over time.

Assay Technologies and Readouts at a Glance

No single detection chemistry covers every stage of degrader development. Choosing among the available protein quantification methods depends on how much target sensitivity, throughput, and true quantitation a given stage of the workflow requires — from primary screening through orthogonal confirmation and unbiased proteome-wide profiling.

Technology Format Sensitivity Throughput Quantitation Best-fit use case
HiBiT / split luciferase Live-cell luminescence High High (384-well) Quantitative Kinetic dose-response, DC50/Dmax, washout studies
NanoLuc fusion reporters Live-cell luminescence High High Quantitative Continuous target-abundance tracking without antibodies
TR-FRET / HTRF Homogeneous fluorescence High High Quantitative Low-abundance targets, lysate dose-response
AlphaLISA Bead-based, wash-free High High Quantitative Crude lysates, low-abundance target detection
Western blot Gel-based, antibody detection Moderate Low Semi-quantitative Identity confirmation, isoform specificity, MOA controls
ELISA Plate-based, antibody capture Moderate–high Moderate Quantitative Orthogonal confirmation of absolute protein abundance
Mass spectrometry Label-free / proteomics Very high (multiplexed) Low–moderate Quantitative (relative/absolute) Proteome-wide selectivity and off-target profiling

Live-cell luminescent reporters and homogeneous fluorescence formats are generally the fastest routes to a quantitative dose-response, while antibody-based protein detection methods and mass spectrometry provide the orthogonal, identity-confirming evidence that a screening result reflects genuine target loss rather than an assay artifact.

Mechanism Validation & High-Throughput Screening

Before a candidate degrader advances into optimization, it is worth confirming that it engages its target through a productive, degradation-competent mechanism rather than simple occupancy. A compound can bind its target, recruit an E3 ligase, and even form a stable ternary complex without ever driving productive turnover — so mechanism-validation controls are what confirm that observed target loss reflects genuine proteasomal degradation pathway activity, rather than target binding alone, general cytotoxicity, or a stable but nonproductive ternary complex that never engages the ubiquitin-proteasome machinery.

PROTAC and Molecular Glue Screening Workflow

Both PROTACs and molecular glues are typically progressed through the same staged sequence of evidence, building from binary binding to a fully validated cellular degradation profile:

1

Target & E3-ligase binding

Confirm binary affinity for the target and for the recruited E3 ligase independently.

2

Ternary-complex assessment

Determine whether the compound cooperatively assembles a stable target–degrader–E3 complex.

3

Cellular degradation confirmation

Verify concentration- and time-dependent target loss in live cells using HiBiT and orthogonal readouts.

4

Lead optimization

Refine DC50, Dmax, kinetics, and selectivity across analog series to select a development candidate.

PROTAC & Molecular Glue Evaluation

We assess whether a candidate molecule drives the specific molecular events required for degradation, including:

  • Ternary complex formation between target, degrader, and E3 ligase
  • E3 ligase recruitment and complex stability
  • Confirmation of a productive, degradation-competent mechanism
  • Assessment of degradation potential ahead of full dose-response profiling

Benefits

  • Earlier identification of functional degraders
  • Improved candidate prioritization
  • Fewer wasted optimization cycles

Knock-In Cell Line Screening Platform

Screening is run in physiologically relevant knock-in cell models rather than overexpression systems, supporting:

  • Endogenous-level target expression for biologically meaningful readouts
  • Broad, diverse target coverage, including undruggable and low-abundance proteins
  • Scalable, high-throughput screening workflows
  • Applications across novel and previously intractable target classes

Benefits

  • More predictive biological assessment
  • Screening workflows that scale with campaign size
  • Greater translational relevance to native cell biology

Ternary Complex and Target Engagement

Strong binary target engagement alone does not reliably predict productive degradation, which is why ternary-complex confirmation is run alongside — not instead of — binary binding and cellular target-engagement data. Three complementary layers of evidence are typically combined:

  • Binary binding assays — biophysical or biochemical measurement of degrader affinity for the target protein and, separately, for the recruited E3 ligase
  • Cellular target-engagement assays — confirmation that the compound engages its target inside intact cells, at physiologically relevant concentrations, rather than only in a purified biochemical system
  • Ternary-complex assays — proximity-based readouts (such as TR-FRET or AlphaLISA formats) that detect cooperative, three-body complex formation between target, degrader, and E3 ligase

A compound that engages both partners individually but fails to form a cooperative ternary complex is unlikely to drive efficient degradation — which is why ternary-complex data, rather than binary affinity alone, is treated as the more predictive gate before advancing a candidate into cellular degradation assays.

Mechanism-of-Action Validation Controls

A defined control panel separates genuine, pathway-dependent degradation from artifacts, and is applied before any compound advances on the strength of a single degradation readout:

  • Proteasome-inhibitor rescue — co-treatment with a proteasome inhibitor (e.g., bortezomib or MG132) should block target loss if degradation is genuinely proteasome-dependent
  • E1/E3 ligase dependency — loss of degradation upon E1 or E3 ligase inhibition or knockdown confirms reliance on an intact ubiquitination mechanism
  • Competitive-ligand controls — excess free target- or ligase-binding ligand should outcompete ternary complex formation and restore target levels
  • Inactive (epimer or non-binding) analogs — structurally similar compounds unable to engage the target or E3 ligase should show no degradation
  • Cell viability counterscreens — parallel viability assessment rules out cytotoxicity as the cause of apparent target loss
  • Target-rescue expression — re-expressing the target protein should restore signal, confirming specificity of the observed loss
PROTAC and molecular glue mechanism diagram Schematic showing a PROTAC bridging a target protein and E3 ligase to form a ternary complex, polyubiquitination of the target, and degradation by the proteasome; a molecular glue pathway is shown in parallel. PROTAC-Induced Degradation Target linker E3 ligase recruitment Ternary Complex poly-ubiquitin chain 26S Proteasome degraded peptides Molecular Glue–Induced Degradation Target glue E3 Directly stabilizes a novel protein-protein interface, recruiting the E3 ligase without a dedicated linker
Mechanistic evaluation of degrader-induced protein degradation pathways.

Schematic illustration for reference; not experimental data.

HiBiT Protein Degradation Reporter System

Endpoint methods such as a single-timepoint Western blot confirm that degradation occurred, but they say little about how fast it happened, how complete it was, or whether it reverses after compound washout. A live-cell HiBiT reporter addresses that gap by functioning as a continuous, quantitative protein quantification assay rather than a single snapshot.

Live-Cell Measurement vs. Endpoint Lysate Methods

Lysate-based protein quantification methods — Western blot, ELISA, and most plate-based immunoassays — necessarily destroy the sample at a single timepoint, so each additional timepoint or dose requires a fresh set of wells. A live-cell HiBiT reporter instead reads the same population of cells repeatedly, which supports:

  • Continuous, real-time monitoring of degradation without harvesting cells
  • Full kinetic curves from a single plate, rather than reconstructed time-courses across separate lysate preparations
  • Washout and recovery studies that track the same cell population before and after compound removal
  • Preservation of native cellular context throughout the measurement window

Real-Time Quantification of Protein Degradation

The target protein of interest is tagged with the small HiBiT peptide at the endogenous locus using knock-in cell engineering. Because the tag is small, it preserves native expression and regulation while enabling continuous luminescent protein detection of abundance. This supports:

  • DC50 determination (the compound concentration producing half-maximal degradation)
  • Dmax calculation (the maximum degradation achieved at plateau)
  • Degradation half-life, onset rate, and recovery kinetics after compound washout

Benefits

  • Quantitative, reproducible degradation assessment
  • Kinetic resolution that endpoint assays cannot provide
  • Clearer understanding of degrader mechanism and durability

High-Throughput Screening Applications

Because the HiBiT/LgBiT complementation reaction is homogeneous, the assay format is well suited to campaign-scale screening:

  • Antibody-free detection, removing a major source of assay variability
  • 96-well and 384-well plate compatibility
  • Short assay turnaround from plating to readout
  • Throughput that scales with library size

Benefits

  • Faster hit identification
  • Higher-throughput screening campaigns
  • Reduced assay complexity and handling steps
Representative HiBiT dose-response degradation curve Sigmoidal dose-response curve showing percent target protein remaining decreasing as compound concentration increases, with DC50 marked at the inflection point and Dmax marked at the plateau. 100% 50% 0% % Target Remaining Compound Concentration (log nM) 1 10 100 1000 DC50 Dmax plateau HiBiT degradation curve
Representative HiBiT degradation curve demonstrating quantitative assessment of degrader potency.

Illustrative curve shape for reference; not derived from a specific compound.

DC50
The compound concentration required to achieve half-maximal target degradation; the primary potency metric for a degrader.
Dmax
The maximum percentage of target protein removed at the assay plateau, describing degradation efficiency independent of potency.
Degradation half-life & onset rate
How quickly target loss begins and progresses after compound treatment, distinguishing fast- from slow-acting degraders.
Recovery after washout
The rate at which target protein levels return once compound is removed, indicating whether degradation is transient or durable.

Hook effect

Reduced degradation at very high concentrations, caused by binary target- or ligase-bound species outcompeting productive ternary complex formation — a common source of misleading dose-response data if compounds are not tested across a wide concentration range.

Multi-Dimensional Quantitative Detection

Orthogonal analytical methods provide additional confidence when characterizing degrader activity, particularly for confirming HiBiT results against label-free or antibody-based protein detection methods. Western blot and ELISA are generally sufficient to confirm degradation of a single, defined target; profiling broader selectivity, downstream pathway effects, or unintended off-target protein loss typically calls for unbiased quantitative proteomics or multiplexed immunoassay panels layered on top of these targeted readouts.

Traditional Validation Methods

Western blot

  • Direct confirmation of target protein expression changes
  • Visual verification of dose- and time-dependent degradation
  • Useful for confirming specificity against related protein isoforms

ELISA

  • Quantitative measurement of protein abundance
  • Orthogonal validation independent of luminescent reporters

Benefits

  • Independent confirmation of degradation activity
  • Higher confidence in experimental findings before advancing a candidate

Advanced Quantitative Technologies

HTRF (TR-FRET)

  • Homogeneous, wash-free assay format
  • High sensitivity suited to low-abundance targets
  • Quantitative degradation measurement across dose-response ranges

AlphaLISA

  • Wash-free workflow compatible with complex lysate matrices
  • Strong performance for low-abundance target detection

Benefits

  • High sensitivity across a broad dynamic range
  • Increased throughput relative to blot-based methods
  • Reliable, reproducible potency assessment

Selectivity, Off-Target Effects, and Proteomics

A degrader's activity against its intended target is only part of the safety and mechanism picture. Because a single E3 ligase can, in principle, be recruited toward unintended neo-substrates, selectivity assessment benefits from methods that look beyond one protein at a time:

  • Quantitative proteomics to survey global changes in protein abundance and flag unanticipated off-target loss
  • Multiplex immunoassay panels to monitor a curated set of pathway-relevant proteins alongside the primary target
  • Western blot panels against structurally related family members to confirm isoform-level specificity

These unbiased and multiplexed approaches complement, rather than replace, the targeted single-protein readouts used for potency determination.

Illustrative Western blot showing dose-dependent degradation Dose-Dependent Degradation Target Loading ctrl DMSO High dose increasing compound concentration
Illustrative Western blot showing time-course degradation Time-Course Degradation 0h 24h increasing treatment time

Orthogonal validation of degrader activity using Western Blot analysis. Illustrative panels for reference; not experimental data.

Illustrative HTRF dose-response curve HTRF Signal vs. Concentration Signal log[Compound] IC50
Illustrative AlphaLISA degradation plot AlphaLISA Degradation Plot % Remaining log[Compound] DC50

Sensitive quantification of protein degradation using HTRF and AlphaLISA technologies. Illustrative curve shapes for reference; not derived from specific compounds.

Detection Technology and Microplate Selection

Selecting the right detection format and plate type reduces interference and keeps a protein quantification assay compatible with automated, miniaturized screening:

  • Luminescence (HiBiT/NanoLuc) — pairs with opaque white plates to maximize signal and minimize crosstalk between wells
  • Fluorescence and TR-FRET/HTRF — pairs with black or low-fluorescence plates to limit background and autofluorescence interference
  • Alpha-based formats (AlphaLISA) — donor/acceptor bead chemistry tolerates crude lysates but requires light-protected handling and white or half-area plates
  • Absorbance (colorimetric ELISA) — standard clear-bottom plates; simple to automate but generally less sensitive than fluorescence or luminescence
  • Imaging-based detection — used when spatial or single-cell resolution of degradation is needed, at some cost to throughput

All of the plate-based formats above are compatible with 384-well layouts and standard liquid-handling automation, which supports miniaturization for screening-scale throughput without sacrificing assay quality.

Positive & negative controls
Each run includes a known active degrader (positive control) and vehicle/DMSO (negative control) to anchor the assay window and confirm the plate performed as expected.
Normalization
Signal is normalized to a loading control (Western blot), an internal reference protein (ELISA/HTRF/AlphaLISA), or a co-expressed luminescent control (HiBiT) to correct for well-to-well variability.
Cell viability counterscreens
Run in parallel with every degradation dose-response to rule out cytotoxicity as the source of apparent target loss.
Reporter & antibody validation
Knock-in reporter clones and detection antibodies are validated for target specificity before use in screening, reducing a common source of false-positive or false-negative degradation calls.
Biological replicates
Independent biological replicates, not just technical replicates, are used to confirm that a degradation result is reproducible rather than a single-experiment artifact.
Common troubleshooting flags
Unexplained loss at only the highest doses points to a hook effect; degradation that persists under proteasome inhibition points to an artifact or an autophagy-lysosomal mechanism rather than proteasomal clearance.

Downstream Functional Readouts

Confirming that a target protein has been removed is necessary but not sufficient — a full characterization also asks whether that loss produces the intended biological consequence. Pairing degradation data with functional readouts closes the loop between target engagement and downstream biology.

Pathway and Signaling Readouts

  • Phosphoprotein assays that track changes in downstream signaling activity following target loss
  • Pathway-biomarker measurements that confirm expected shifts in disease-relevant signaling nodes
  • Transcriptional readouts that capture changes in target-gene expression driven by loss of the degraded protein

Cellular and Phenotypic Readouts

  • Cell viability and proliferation assays to determine whether degradation translates into an anti-proliferative or cytotoxic effect where expected
  • Phenotypic assays tailored to the disease biology, capturing a functional endpoint beyond protein abundance
  • Time-matched comparison against degradation kinetics to confirm that phenotype follows target loss rather than an off-target effect

Layering these functional endpoints onto DC50, Dmax, and orthogonal protein quantification data gives a more complete mechanistic picture: not just that the target disappeared, but that its disappearance produced the expected downstream biology.

Why Partner with Us for Protein Degradation Studies

Integrated Platform

One workflow spanning mechanism validation through quantitative degradation assessment, rather than disconnected assay vendors.

Physiologically Relevant Models

Knock-in cell lines expressing tagged targets at endogenous levels support biologically meaningful evaluation.

Multiple Orthogonal Readouts

HiBiT, Western blot, ELISA, HTRF, and AlphaLISA readouts confirm findings across independent detection chemistries.

High-Throughput Capabilities

96- and 384-well compatible formats support large-scale degrader screening campaigns without sacrificing data quality.

Scientific Collaboration

Direct support for experimental design, execution, and data interpretation throughout your discovery program.

Advance Your Protein Degradation Program

Generate robust, quantitative insights into degrader activity using integrated assays designed for PROTAC and molecular glue development.